The Behcet't Disease Quality of Life: Reliability and Validity of the Korean Version.
10.3349/ymj.2008.49.5.698
- Author:
Sang Won YI
1
;
Ji Hae KIM
;
Ki Young LIM
;
Dongsik BANG
;
Sungnack LEE
;
Eun So LEE
Author Information
1. Department of Dermatology and Psychiatry, Ajou University School of Medicine, Suwon, Korea. esl@ajou.ac.kr
- Publication Type:Original Article ; Validation Studies
- Keywords:
Adaptation;
Behcet's disease;
quality of life;
reliability;
validity
- MeSH:
Adolescent;
Adult;
Aged;
Behcet Syndrome/diagnosis/*psychology/therapy;
Child;
Cultural Characteristics;
Female;
Humans;
Korea;
Language;
Male;
Middle Aged;
*Quality of Life;
Questionnaires/*standards
- From:Yonsei Medical Journal
2008;49(5):698-704
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The Behcet's Disease Quality of Life (BD-QoL) is a BD-specific measure developed in the UK. The aim of this study was to adapt the BD-QoL for use in Korea. PATIENTS AND METHODS: The translation was based on the guidelines for cross-cultural adaptation. A total of 201 Korean patients with BD participated in this study. To evaluate the psychometric properties, internal consistency and test-retest reliability were used. Factor analysis was performed to examine the construct validity. To provide further evidence for validity, the correlation of BD-QoL with the Clinical Activity Form for Korean Patients with BD (BDCAF-K) and the Center for Epidemiologic Studies-Depression (CES-D) scales was assessed. RESULTS: The Korean version had high internal consistency (Cronbach's alpha, 0.93) and test-retest reliability (r = 0.835). Factor analysis of the questionnaire revealed one interpretable factor as a general health-related quality of life factor. The Korean version significantly correlated with scores of CES-D (r = 0.749, p = 0.000), self-rating scale of well-being over the past 28 days (r = 0.446, p = 0.000), and BDCAF-K score (r = 0.502, p = 0.000). CONCLUSION: Adaptation of the BD-QoL for use in Korea was successful. Together with the BDCAF-K, it may be a valuable tool for assessing the influence of interventions in BD patients and outcome in clinical trials.
